LUPKYNIS sales - The company attributed Q2 revenue growth to higher sales of LUPKYNIS for lupus nephritis
Operating expenses - Lower operating expenses contributed to improved profitability in Q2
License and royalty revenue - Growth in license, collaboration and royalty revenue supported the overall revenue increase
Guidance and capital return
Aurinia reiterated 2026 total revenue guidance of $315 mln to $325 mln
The company expects 2026 net product sales of $305 mln to $315 mln
Aurinia repurchased 5 mln shares for $74.9 mln in H1 2026
Quarterly revenue and profit rise
Canada biopharma's Q2 diluted EPS for Q2 increased 75% yr/yr
Q2 total revenue was $83.2 mln, with net income of $37.41 mln, operating expenses of $36.88 mln, operating income of $46.34 mln and pretax profit of $48.79 mln
AUPH•
